Contemporary management of high-risk localized prostate cancer

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The management of high-risk, localized prostate cancer remains a formidable challenge despite significant technical advances in surgery and radiation therapy. Treatment outcomes of radiation therapy are improved by the addition of adjuvant androgen deprivation therapy, whereas, with surgery, oncologic results are enhanced with either postoperative radiation therapy or androgen deprivation therapy in select cases. In high-risk prostate cancer, disease recurrence after primary therapy may occur at either distant or local sites. Ongoing studies are in the process of evaluating systemic therapy for the eradication of local and micrometastatic disease. Neoadjuvant therapies offer the opportunity to maximize local control as a path to improved outcomes and critically evaluate agent effectiveness in the target tissue. The treatment for high-risk localized prostate cancer is in evolution. It is likely that the development of effective strategies based on understanding prostate tumor biology will lead to significant advances in the treatment of this disease.

Original languageEnglish (US)
Pages (from-to)159-164
Number of pages6
JournalCurrent Urology Reports
Volume11
Issue number3
DOIs
StatePublished - May 2010

Fingerprint

Risk Management
Prostatic Neoplasms
Radiotherapy
Androgens
Therapeutics
Neoadjuvant Therapy
Prostate
Recurrence
Neoplasms

Keywords

  • Adjuvant
  • Androgens
  • Chemotherapy
  • Gleason score
  • Neoadjuvant
  • Prostate cancer
  • Prostatectomy
  • Radiation

ASJC Scopus subject areas

  • Urology
  • Medicine(all)

Cite this

Contemporary management of high-risk localized prostate cancer. / Garzotto, Mark; Hung, Arthur.

In: Current Urology Reports, Vol. 11, No. 3, 05.2010, p. 159-164.

Research output: Contribution to journalArticle

@article{5775a1a36e244de88fed0e5ae78fb31d,
title = "Contemporary management of high-risk localized prostate cancer",
abstract = "The management of high-risk, localized prostate cancer remains a formidable challenge despite significant technical advances in surgery and radiation therapy. Treatment outcomes of radiation therapy are improved by the addition of adjuvant androgen deprivation therapy, whereas, with surgery, oncologic results are enhanced with either postoperative radiation therapy or androgen deprivation therapy in select cases. In high-risk prostate cancer, disease recurrence after primary therapy may occur at either distant or local sites. Ongoing studies are in the process of evaluating systemic therapy for the eradication of local and micrometastatic disease. Neoadjuvant therapies offer the opportunity to maximize local control as a path to improved outcomes and critically evaluate agent effectiveness in the target tissue. The treatment for high-risk localized prostate cancer is in evolution. It is likely that the development of effective strategies based on understanding prostate tumor biology will lead to significant advances in the treatment of this disease.",
keywords = "Adjuvant, Androgens, Chemotherapy, Gleason score, Neoadjuvant, Prostate cancer, Prostatectomy, Radiation",
author = "Mark Garzotto and Arthur Hung",
year = "2010",
month = "5",
doi = "10.1007/s11934-010-0101-0",
language = "English (US)",
volume = "11",
pages = "159--164",
journal = "Current Urology Reports",
issn = "1527-2737",
publisher = "Current Science, Inc.",
number = "3",

}

TY - JOUR

T1 - Contemporary management of high-risk localized prostate cancer

AU - Garzotto, Mark

AU - Hung, Arthur

PY - 2010/5

Y1 - 2010/5

N2 - The management of high-risk, localized prostate cancer remains a formidable challenge despite significant technical advances in surgery and radiation therapy. Treatment outcomes of radiation therapy are improved by the addition of adjuvant androgen deprivation therapy, whereas, with surgery, oncologic results are enhanced with either postoperative radiation therapy or androgen deprivation therapy in select cases. In high-risk prostate cancer, disease recurrence after primary therapy may occur at either distant or local sites. Ongoing studies are in the process of evaluating systemic therapy for the eradication of local and micrometastatic disease. Neoadjuvant therapies offer the opportunity to maximize local control as a path to improved outcomes and critically evaluate agent effectiveness in the target tissue. The treatment for high-risk localized prostate cancer is in evolution. It is likely that the development of effective strategies based on understanding prostate tumor biology will lead to significant advances in the treatment of this disease.

AB - The management of high-risk, localized prostate cancer remains a formidable challenge despite significant technical advances in surgery and radiation therapy. Treatment outcomes of radiation therapy are improved by the addition of adjuvant androgen deprivation therapy, whereas, with surgery, oncologic results are enhanced with either postoperative radiation therapy or androgen deprivation therapy in select cases. In high-risk prostate cancer, disease recurrence after primary therapy may occur at either distant or local sites. Ongoing studies are in the process of evaluating systemic therapy for the eradication of local and micrometastatic disease. Neoadjuvant therapies offer the opportunity to maximize local control as a path to improved outcomes and critically evaluate agent effectiveness in the target tissue. The treatment for high-risk localized prostate cancer is in evolution. It is likely that the development of effective strategies based on understanding prostate tumor biology will lead to significant advances in the treatment of this disease.

KW - Adjuvant

KW - Androgens

KW - Chemotherapy

KW - Gleason score

KW - Neoadjuvant

KW - Prostate cancer

KW - Prostatectomy

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=77952236883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952236883&partnerID=8YFLogxK

U2 - 10.1007/s11934-010-0101-0

DO - 10.1007/s11934-010-0101-0

M3 - Article

VL - 11

SP - 159

EP - 164

JO - Current Urology Reports

JF - Current Urology Reports

SN - 1527-2737

IS - 3

ER -